Tolmar, Inc., a specialty pharmaceutical company, has established its new Northern Illinois Laboratory at Rosalind Franklin University’s Innovation and Research Park (IRP) in North Chicago, Illinois. This facility enhances Tolmar’s capabilities in developing and commercializing pharmaceutical products and strengthens the university’s ecosystem of industry innovation.
Founded in 2007, Tolmar is recognized globally for its expertise in long-acting injectable drug delivery. The company specializes in the development and manufacturing of injectables targeting urology, oncology, and endocrinology. Its flagship product, which treats advanced prostate cancer, is marketed in 89 countries.
Collaboration and Regional Growth
The new laboratory at RFU’s IRP is designed to complement Tolmar’s existing facilities in Colorado, featuring a team of experienced researchers, engineers, and operations staff. This expansion also increases Tolmar’s regional presence, which includes executive offices and sales and marketing teams based in Buffalo Grove, Illinois.
Dr. Dave Loffredo, Vice President of Innovation at Tolmar, expressed enthusiasm about the new site: “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”
Dr. Stace Porter, Senior Vice President of Development Operations at Tolmar, highlighted the lab’s potential within RFU’s Research Park. “Here, we gain world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he stated. “We’re excited to grow and innovate here.”
Innovative Research Environment
The IRP spans 100,000 square feet and houses six research centers, including the Center for Cancer Cell Biology, Immunology and Infection. Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to the university’s community of innovators. “We look forward to collaborations that can help accelerate new product development,” he remarked. “The IRP provides an environment that fosters the kind of intellectual biomedical collisions that drive meaningful innovation.”
As Tolmar integrates into the Innovation and Research Park, the collaboration with RFU is expected to enhance the development of new pharmaceuticals, benefiting both the company and the broader healthcare landscape.
For more information about Tolmar, visit www.tolmar.com. To learn more about Rosalind Franklin University, please go to rosalindfranklin.edu.
